Search Results

Pexmetinib 100 mg  | 99.07%

TargetMol

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

More Information Supplier Page

Selisistat 25 mg  | 99.67%

TargetMol

EX 527 is an effective and specific SIRT1 inhibitor (IC50: 38 nM) and shows >200-fold selectivity against SIRT2/3.

More Information Supplier Page

Cyclopamine 100 mg  | Purity Not Available

TargetMol

Cyclopamine, a Smoothened (Smo) antagonist (IC50: 46 nM in TM3Hh12 cells), belongs to the group of steroidal jerveratrum alkaloids.

More Information Supplier Page

Pexmetinib 50 mg  | 99.07%

TargetMol

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

More Information Supplier Page

Pexmetinib 2 mg  | 99.07%

TargetMol

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

More Information Supplier Page

Selisistat 200 mg  | 99.67%

TargetMol

EX 527 is an effective and specific SIRT1 inhibitor (IC50: 38 nM) and shows >200-fold selectivity against SIRT2/3.

More Information Supplier Page

Selisistat 100 mg  | 99.67%

TargetMol

EX 527 is an effective and specific SIRT1 inhibitor (IC50: 38 nM) and shows >200-fold selectivity against SIRT2/3.

More Information Supplier Page

Selisistat 50 mg  | 99.67%

TargetMol

EX 527 is an effective and specific SIRT1 inhibitor (IC50: 38 nM) and shows >200-fold selectivity against SIRT2/3.

More Information Supplier Page